The Global Drug sales of Otezla stood at USD 2,288 Millions in 2022
The indicator recorded a historical growth (CAGR) of13% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Apremilast (Otezla) is a musculoskeletal system agent. It is formulated as a film-coated tablet for oral administration.
Mechanism of Action
Apremilast is a PDE4 inhibitor. PDE4 inhibits the expression of anti-inflammatory cytokines such as interleukin (IL)-10 in a protein kinase A-dependent manner. The drug candidate also blocks the synthesis of other pro-inflammatory cytokines and chemokines such as tumor necrosis factor alpha, IL 23, CXCL9, and CXCL10 in multiple cell types. Inhibition of PDE 4 regulates IL-8 and IP-10 expression and TNF-a production by keratinocytes. Cellular immune system triggered keratinocyte response is implicated in the pathogenesis of psoriasis. A cytokine produced by immune cells and synovial fibroblasts in the inflamed synovium enhances the inflammatory response in arthritis. Autoimmune disorders are also highlighted by the heightened immune response and inflammatory responses. The drug candidate binds to the catalytic site of the PDE4 enzyme thereby blocking cAMP degradation. This results in inhibition of TNF-a gene expression and subsequent immune responses.
Otezla Overview
Otezla is marketed for the treatment of several indications in Hematological Disorders, and Toxicology therapy areas.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis. It is also indicated in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Otezla used alone or in combination with disease-modifying antirheumatic drugs for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or were an intolerant to previous DMARD therapy and in pediatric patients, indicated for the treatment of chronic plaque psoriasis moderate to severe in adult patients who have not responded, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet type A PUVA), and for the treatment of adult and pediatric patients with oral ulcers associated with Behçet’s Disease.
Otezla was first approved in 2014 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Celgene Corp, and Amgen Inc. Otezla drug sales recorded a mid-double digit Year on Year growth in 2021. Otezla drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
China
Switzerland
United States of America
United States of America
United States of America
Germany
France
Switzerland
United States of America
United Kingdom
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer